CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

1.8950
1.04%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0200
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.915
Open 1.915
1-Year Change -11.45%
Day's Range 1.885 - 1.945
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 18, 2024 1.8950 0.0000 0.00% 1.8950 1.9450 1.8850
Jun 17, 2024 1.9150 -0.0600 -3.04% 1.9750 2.0050 1.7950
Jun 14, 2024 2.0150 -0.0400 -1.95% 2.0550 2.1150 1.9750
Jun 13, 2024 2.0950 0.0900 4.49% 2.0050 2.1550 2.0050
Jun 12, 2024 2.0650 -0.1100 -5.06% 2.1750 2.1750 2.0350
Jun 11, 2024 2.1150 0.0500 2.42% 2.0650 2.1850 1.9950
Jun 10, 2024 2.0850 0.0800 3.99% 2.0050 2.1250 1.9750
Jun 7, 2024 2.0150 0.0100 0.50% 2.0050 2.1750 2.0050
Jun 6, 2024 2.0650 -0.1100 -5.06% 2.1750 2.1950 2.0050
Jun 5, 2024 2.1850 0.0900 4.30% 2.0950 2.2650 2.0950
Jun 4, 2024 2.1350 -0.0100 -0.47% 2.1450 2.2250 2.0950
Jun 3, 2024 2.1850 0.0900 4.30% 2.0950 2.2250 2.0650
May 31, 2024 2.1350 0.0700 3.39% 2.0650 2.1750 2.0550
May 30, 2024 2.1050 0.0500 2.43% 2.0550 2.1850 2.0250
May 29, 2024 2.0750 0.0800 4.01% 1.9950 2.1250 1.9450
May 28, 2024 2.0150 0.0000 0.00% 2.0150 2.0550 1.9250
May 24, 2024 2.0450 0.0300 1.49% 2.0150 2.0950 1.9950
May 23, 2024 2.0550 -0.0200 -0.96% 2.0750 2.1150 1.9550
May 22, 2024 2.1350 -0.0200 -0.93% 2.1550 2.2150 2.0850
May 21, 2024 2.1750 -0.0300 -1.36% 2.2050 2.2750 2.1550

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Corvus Pharmaceuticals, Inc. Company profile

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.

Industry: Biotechnology & Medical Research (NEC)

863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US

News

Bank of England preview: no rate cut just yet despite CPI returning to 2%

The Bank of England (BoE) is widely expected to keep rates unchanged when it meets on Thursday. Analyst Daniela Harthorn looks at what this could mean

12:45, 18 June 2024

RBA Meeting Preview: No change to policy expected, markets look for fresh guidance

The Reserve Bank of Australia is expected to keep interest rates unchanged at 4.35% when it meets on Tuesday, June 18th, 2024, at 2:30 PM (AEST).

13:17, 17 June 2024

FOMC Decision Review: Rates unchanged as central bank raises inflation and interest rate forecasts

The FOMC left Federal Funds Rate unchanged at a target range of 5.25 to 5.50%.

10:55, 17 June 2024

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

People also watch

BTC/USD

65,164.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

ETH/USD

3,537.94 Price
+2.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,949.30 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,329.99 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.40

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading